Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | March 19, 2019 | March 21, 2019 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date March 19, 2019 · Filed March 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,141 |
Reported balance
After 2019-03-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-03-19 · Grant · Acquired 7,569 · Balance 56,141 F2: Mr. Mulligan and his family, collectively hold an aggregate 100% equity interest in Nerano Pharma Ltd, which in turn is the direct owner of 545,590 shares of the Issuer's common stock. F1: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
| Common StockSEC Table I · non-derivative | IndirectBy Nerano Pharma Ltd | 545,590 |
Reported balance
Holding disclosure · report date 2019-03-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 545,590 F2: Mr. Mulligan and his family, collectively hold an aggregate 100% equity interest in Nerano Pharma Ltd, which in turn is the direct owner of 545,590 shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2: Mr. Mulligan and his family, collectively hold an aggregate 100% equity interest in Nerano Pharma Ltd, which in turn is the direct owner of 545,590 shares of the Issuer's common stock.
Jazz Pharmaceuticals plc
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,184,633 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Grant · Acquired 1,605 · Balance 1,184,633 F1: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Nerano Pharma Lim | 101,621 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 101,621 F2: Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.
F2: Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 21:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001536639-26-000004 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,184,633 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,415 | $0.00 Strike: $138.08 | $0.00 |
DisclosureSEC source: 0001536639-26-000002 · edgardoc.xml · derivative · entry 3 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,415 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This non-qualified stock option was granted on August 11, 2016 and vested over the period from September 1, 2016 through August 1, 2017. The options were fully vested as of August 1, 2017. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 3,415 | $138.08 | $471,543.20 |
DisclosureSEC source: 0001536639-26-000002 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,183,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000076 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,179,613 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026. Read SEC document |
| May 12, 2025 Filed May 13, 2025 22:51 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 1,621 | $103.00 | $166,961.54 |
DisclosureSEC source: 0001765581-25-000042 · edgardoc.xml · nonDerivative · entry 4 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Nerano Pharma Lim Disclosed balance after: 101,621 F4 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $102.97 to $103.00. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. F2 · ownership.nature: Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. Read SEC document |
| May 09, 2025 Filed May 13, 2025 22:51 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 100 | $99.71 | $9,971.00 |
DisclosureSEC source: 0001765581-25-000042 · edgardoc.xml · nonDerivative · entry 3 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Nerano Pharma Lim Disclosed balance after: 100,000 F2 · ownership.nature: Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. Read SEC document |
| May 09, 2025 Filed May 13, 2025 22:51 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 19,216 | $98.91 | $1,900,677.62 |
DisclosureSEC source: 0001765581-25-000042 · edgardoc.xml · nonDerivative · entry 2 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Nerano Pharma Lim Disclosed balance after: 99,900 F3 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $98.56 to $99.47. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. F2 · ownership.nature: Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. Read SEC document |
| May 09, 2025 Filed May 13, 2025 22:51 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 80,684 | $98.10 | $7,915,471.55 |
DisclosureSEC source: 0001765581-25-000042 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Nerano Pharma Lim Disclosed balance after: 80,684 F1 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $97.56 to $98.5542. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. F2 · ownership.nature: Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000070 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,176,106 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 25, 2025. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000086 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,172,375 F1 · kind: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $81.76 | $0.00 |
DisclosureSEC source: 0001765581-23-000052 · edgardoc.xml · derivative · entry 2 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,500 shares Expires 2023-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This non-qualified stock option was granted on August 8, 2013 and vested over a period of one year from September 1, 2013. The options were fully vested as of August 1, 2014. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 4,500 | $81.76 | $367,920.00 |
DisclosureSEC source: 0001765581-23-000052 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,169,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2023 Filed Mar 8, 2023 01:30 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $59.13 | $0.00 |
DisclosureSEC source: 0001765581-23-000010 · edgardoc.xml · derivative · entry 2 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,500 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Option Plan and vested in 12 monthly installments over one year from the grant date, March 5, 2013. Read SEC document |
| March 04, 2023 Filed Mar 8, 2023 01:30 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 4,500 | $59.13 | $266,085.00 |
DisclosureSEC source: 0001765581-23-000010 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,164,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 22:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000090 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,160,300 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:18 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000075 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,157,739 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,765 | $0.00 Strike: $127.07 | $0.00 |
DisclosureSEC source: 0001765581-20-000075 · edgardoc.xml · derivative · entry 2 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Underlying: Ordinary Shares · 6,765 shares Expires 2030-08-05 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000075 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155,493 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 11,482 | $112.32 | $1,289,645.61 |
DisclosureSEC source: 0001765581-20-000055 · edgardoc.xml · nonDerivative · entry 5 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,152,788 F5 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $112.0500 to $112.6600. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 9,884 | $111.56 | $1,102,681.77 |
DisclosureSEC source: 0001765581-20-000055 · edgardoc.xml · nonDerivative · entry 4 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141,306 F4 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $111.0350 to $112.0200. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 8,391 | $110.52 | $927,351.50 |
DisclosureSEC source: 0001765581-20-000055 · edgardoc.xml · nonDerivative · entry 3 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,131,422 F3 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from 110.0300 to $111.0100. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 5,243 | $109.55 | $574,379.04 |
DisclosureSEC source: 0001765581-20-000055 · edgardoc.xml · nonDerivative · entry 2 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,031 F2 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $109.0300 to $110.0200. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| May 26, 2020 Filed May 27, 2020 22:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 15,000 | $110.65 | $1,659,747.00 |
DisclosureSEC source: 0001765581-20-000055 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,117,788 F1 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $110.1800 to $110.9800. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,805 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001765581-19-000068 · edgardoc.xml · derivative · entry 2 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Ordinary Shares · 4,805 shares Expires 2029-08-07 F2 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000068 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,788 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2020. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 7,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-007364 · doc1.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,141 F2 · security: Mr. Mulligan and his family, collectively hold an aggregate 100% equity interest in Nerano Pharma Ltd, which in turn is the direct owner of 545,590 shares of the Issuer's common stock. F1 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 22:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 22,137 | $145.05 | $3,210,892.16 |
DisclosureSEC source: 0001232524-18-000196 · edgardoc.xml · nonDerivative · entry 4 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,868 F4 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $144.69 to $145.56. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 22:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 26,363 | $144.24 | $3,802,680.85 |
DisclosureSEC source: 0001232524-18-000196 · edgardoc.xml · nonDerivative · entry 3 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,078,731 F3 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $143.69 to $144.67. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 22:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 1,200 | $143.22 | $171,869.04 |
DisclosureSEC source: 0001232524-18-000196 · edgardoc.xml · nonDerivative · entry 2 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,368 F2 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $142.67 to $143.60. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 22:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 300 | $141.86 | $42,558.99 |
DisclosureSEC source: 0001232524-18-000196 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051,168 F1 · price: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $141.52 to $142.04. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 23:07 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,735 | $0.00 Strike: $177.73 | $0.00 |
DisclosureSEC source: 0001232524-18-000156 · edgardoc.xml · derivative · entry 2 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,735 Underlying: Ordinary Shares · 3,735 shares Expires 2028-08-08 F2 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 23:07 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000156 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,868 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,415 | $0.00 Strike: $143.66 | $0.00 |
DisclosureSEC source: 0001232524-17-000144 · edgardoc.xml · derivative · entry 2 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,415 Underlying: Ordinary Shares · 3,415 shares Expires 2027-08-09 F2 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000144 · edgardoc.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049,373 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. F1 · shares: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.